Search results
Results From The WOW.Com Content Network
Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [6] For the prevention of cardiovascular disease, statins are a first-line treatment in reducing cholesterol. [ 6 ]
Kidney transplantation recipients taking ciclosporin: Pravastatin or fluvastatin: Drug interactions are possible, but studies have not shown that these statins increase exposure to ciclosporin. [61] HIV-positive people taking protease inhibitors: Atorvastatin, pravastatin or fluvastatin: Negative interactions are more likely with other choices ...
Statins are generally recommended for adults between the ages of 40 and 75 who have heart disease risk factors. Despite having higher risks for cardiovascular disease, fewer older adults use statins.
In studies using standard doses, statins have been found to lower LDL-C by 18% to 55%, depending on the specific statin being used. A risk exists of muscle damage (myopathy and rhabdomyolysis) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after ...
However, taking steps to support your heart health can help you lower your risk of many types of cardiovascular disease, such as stroke or heart attacks. This article originally appeared on Hims ...
AstraZeneca (NYS: AZN) just lost a potential marketing edge for Crestor. In trial results announced today, the statin drug failed to best Lipitor at clearing clogged arteries, at least in a ...
A much-aired commercial might prompt patients to discuss conditions they never knew they had, the logic goes, or reduce the stigma around certain diseases. If you see ads for depression or irritable bowel syndrome every night while eating dinner, you might feel less embarrassed asking your doctor about it.
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]